12:00 AM
 | 
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oral Relistor methylnaltrexone: Additional Phase III data

Additional data from a double-blind Phase III trial in 804 patients with chronic, non-cancer pain showed that once-daily 300 and 450 mg oral methylnaltrexone led to respective 24.6% and 27.4% improvements on the primary endpoint of the proportion of patients with an RFBM within 4 hours of treatment each day over 28 days vs. 18.1% for placebo (p=0.004 and p<0.001, respectively). On secondary endpoints, mid- and high-dose oral methylnaltrexone led to a significant 47.8% and 50.5% improvement in the proportion of patients who were considered responders, defined as having >=3 RFBM per week with an increase of >=1 RFBM per week from baseline for >=3 out of the first 4...

Read the full 529 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >